Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
BMC Medicine
|
April 6, 2025
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
Marine Massy, Stefanie Marti, Helly Hammer, et al.
Epilepsia Open
|
June 20, 2025
Inequalities in access to industry-funded interventional phase I-IV drug trials in epilepsy
Robert Hoepner, Alejandro Xavier León Betancourt, Stefanie Marti, et al.
Frontiers in Molecular Biosciences
|
December 19, 2018
A Method for RNA Structure Prediction Shows Evidence for Structure in lncRNAs
Riccardo Delli Ponti, Alexandros Armaos, Stefanie Marti, et al.
Nucleic Acids Research
|
December 1, 2016
A high-throughput approach to profile RNA structure
Riccardo Delli Ponti, Stefanie Marti, Alexandros Armaos, et al.
Frontiers in Pharmacology
|
July 3, 2023
The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
Anke Salmen, Stefanie Marti, Andreas G F Hoepner, et al.
JAMA Network Open
|
November 29, 2023
Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis
Stefanie Marti, Andreas G F Hoepner, Helly Hammer, et al.
Therapeutic Advances in Neurological Disorders
|
March 27, 2024
Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events
Pauline Thränhardt, Admirim Veselaj, Christoph Friedli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 6, 2025
Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?
Gabriel Bsteh, Stefanie Marti, Helly Hammer, et al.
Journal of Central Nervous System Disease
|
May 7, 2024
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study
Christoph Friedli, Nik Krajnc, Helly N Hammer, et al.
Acta Neuropathologica Communications
|
June 18, 2026
Higher disease reactivation risk in women after fingolimod withdrawal
Marine Massy, Stefanie Marti, Adriane Kutllovci, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
BMC Medicine
|
April 6, 2025
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
Marine Massy, Stefanie Marti, Helly Hammer, et al.
Epilepsia Open
|
June 20, 2025
Inequalities in access to industry-funded interventional phase I-IV drug trials in epilepsy
Robert Hoepner, Alejandro Xavier León Betancourt, Stefanie Marti, et al.
Frontiers in Molecular Biosciences
|
December 19, 2018
A Method for RNA Structure Prediction Shows Evidence for Structure in lncRNAs
Riccardo Delli Ponti, Alexandros Armaos, Stefanie Marti, et al.
Nucleic Acids Research
|
December 1, 2016
A high-throughput approach to profile RNA structure
Riccardo Delli Ponti, Stefanie Marti, Alexandros Armaos, et al.
Frontiers in Pharmacology
|
July 3, 2023
The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
Anke Salmen, Stefanie Marti, Andreas G F Hoepner, et al.
JAMA Network Open
|
November 29, 2023
Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis
Stefanie Marti, Andreas G F Hoepner, Helly Hammer, et al.
Therapeutic Advances in Neurological Disorders
|
March 27, 2024
Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events
Pauline Thränhardt, Admirim Veselaj, Christoph Friedli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 6, 2025
Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?
Gabriel Bsteh, Stefanie Marti, Helly Hammer, et al.
Journal of Central Nervous System Disease
|
May 7, 2024
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study
Christoph Friedli, Nik Krajnc, Helly N Hammer, et al.
Acta Neuropathologica Communications
|
June 18, 2026
Higher disease reactivation risk in women after fingolimod withdrawal
Marine Massy, Stefanie Marti, Adriane Kutllovci, et al.
Page
of 2